Phase 2 N=101 Phase II Study of HMPL-004 in Subjects With Crohn's Disease
Crohn's Disease
Primary: CDAI Clinical Response -100 at Week 8 — 19; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=149 Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2
Obesity
Primary: Percent of Subjects Attaining Clinically Successful Weight Loss ( ≥ 30% EWL) at 1 Year Post LAP-BAND Implantation — 83.9 percentage of subjects
Phase 2 N=21 Topical Cyclosporine Suspension for the Treatment of Brittle Nails
Brittle Nail Syndrome
Primary: • Number of Patients Receiving at Least a 1-grade Improvement in the Physicians Global Improvement Assessment (PGIA) of Two Target Nails. — 10; 11 patients
Phase 4 N=83 Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.
Alcohol Dependence
Primary: "Natural" Alcohol Consumption Period; Average Number of Drinks Per Day Consumed During the 5 Day Natural (Usual Environment) Drinking Observation Period — 4.7; 5.7; 6.2…
Phase 4 N=123 Metoclopramide Versus Ketorolac for Tension-type Headache
Headache
Primary: Change in Pain Score — 3.8; 5.1 units on a scale
Phase 4 N=159 Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Hypertension · Hypercholesterolemia · Angina Pectoris
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 120; 11 Participants
Phase 2 N=51 Beta-blockade Effects on Memory for Cocaine Craving
Cocaine Dependence
Primary: Single Item Craving Test Session Difference Scores — -25.0; -10.5 units on a scale
Phase 4 N=425 A Trial Comparing Split-Dose Miralax With Amitiza Pretreatment Versus Dulcolax Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy
Colonoscopy
Primary: The Cleanliness of the Prep as Measured by the Ottawa Scale — 6.3; 6.8; 6.9; 5.1 Ottawa Scale
N/A N=9 Effects of Testosterone in Women With Depression
Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Scale — 25.9; 14.7; 15.2 units on a scale — p=0.002
N/A N=8 Encore Revelation Hip Stem
Osteoarthritis, Hip · Complications; Arthroplasty
Primary: Survivorship of the Device — 8 participants
N/A N=65 RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
Arterial Occlusive Diseases · Myocardial Ischemia · Cardiovascular Diseases
Primary: Target Lesion Failure(TLF) — 4.62 percentage of TLF
Phase 3 N=2,120 Confirmatory Study Nepafenac 0.3%
Cataract
Primary: Percentage of Patients Cured at Day 14 — 68.4; 70.0; 34.0; 35.6 percentage of participants
Phase 3 N=42 Trial of Mifepristone for Fibroids
Leiomyoma
Primary: Uterine Volume — 719; 449 mL
Phase 2 N=44 Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) — 40 percentage of participants
Phase 2 N=20 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
Renal Cell Carcinoma
Primary: Progression-free Survival — 1.7 months